Aurora Cannabis (NASDAQ: ACB) announced in early June an additional round of cost-saving measures as part of its business transformation plan that has already brought on major adjustments to the company in the past two years. Aurora's shares dropped throughout June after it bought back millions of dollars in convertible debt, announced it would close a major facility, and laid off a huge chunk of its workforce. All this is bad news for the international cannabis operator -- but a strong showing in Europe's medical cannabis market, and its major presence in Canadian medical cannabis, should provide long-term hope amid the short-term gloom. Read More...
Aurora Cannabis (NASDAQ: ACB) announced in early June an additional round of cost-saving measures as part of its business transformation plan that has already brought on major adjustments to the company in the past two years. Aurora’s shares dropped throughout June after it bought back millions of dollars in convertible debt, announced it would close a major facility, and laid off a huge chunk of its workforce. All this is bad news for the international cannabis operator — but a strong showing in Europe’s medical cannabis market, and its major presence in Canadian medical cannabis, should provide long-term hope amid the short-term gloom.
Add Comment